Green Alpha Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$74.9K Buy
68,055
+2,475
+4% +$2.94K 0.05% 110
2026
Q1
$114K Sell
65,580
-6,515
-9% -$10.7K 0.11% 100
2025
Q4
$125K Buy
72,095
+24,007
+50% +$52.9K 0.11% 109
2025
Q3
$113K Sell
48,088
-5,220
-10% -$9.99K 0.11% 97
2025
Q2
$108K Sell
53,308
-7,953
-13% -$15.2K 0.1% 100
2025
Q1
$99.9K Sell
61,261
-4,185
-6% -$8.4K 0.11% 102
2024
Q4
$120K Buy
65,446
+33,232
+103% +$147K 0.1% 140
2024
Q3
$186K Sell
32,214
-871
-3% -$7.18K 0.15% 124
2024
Q2
$267K Sell
33,085
-3,332
-9% -$35.1K 0.21% 109
2024
Q1
$505K Sell
36,417
-1,227
-3% -$10.6K 0.37% 98
2023
Q4
$230K Sell
37,644
-9,860
-21% -$48.7K 0.17% 142
2023
Q3
$222K Buy
47,504
+32,313
+213% +$178K 0.17% 139
2023
Q2
$81.4K Buy
15,191
+2,999
+25% +$24.2K 0.05% 147
2023
Q1
$120K Sell
12,192
-64
-0.5% -$1.09K 0.08% 140
2022
Q4
$229K Sell
12,256
-26
-0.2% -$589 0.19% 127
2022
Q3
$254K Buy
12,282
+1,399
+13% +$35.8K 0.22% 129
2022
Q2
$226K Buy
10,883
+4,284
+65% +$121K 0.05% 142
2022
Q1
$284K Buy
6,599
+545
+9% +$24.6K 0.19% 125
2021
Q4
$363K Buy
6,054
+623
+11% +$49.9K 0.25% 117
2021
Q3
$467K Buy
5,431
+217
+4% +$21.8K 0.32% 119
2021
Q2
$580K Buy
+5,214
New +$501K 0.39% 112

Other funds holding INO

Green Alpha Advisors's INO Position: Q2 2026 in Review

Green Alpha Advisors increased its Inovio Pharmaceuticals (INO) stake by 3.8% in Q2 2026, buying an estimated $2.94K and bringing the position to 68,055 shares worth $74.9K. The position accounts for 0.05% of the portfolio, ranked #110.

Green Alpha Advisors first reported a position in INO in Q2 2021 and has held it in 21 quarters since. The position peaked at $580K in Q2 2021. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Green Alpha Advisors held 68,055 shares of Inovio Pharmaceuticals worth $74.9K as of Q2 2026.
  • Green Alpha Advisors bought 2,475 Inovio Pharmaceuticals shares in Q2 2026, an estimated $2.94K.
  • Inovio Pharmaceuticals made up 0.05% of Green Alpha Advisors's portfolio in Q2 2026, its #110 holding.
  • Green Alpha Advisors first reported a position in Inovio Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Green Alpha Advisors's Inovio Pharmaceuticals position peaked at $580K in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Green Alpha Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.